{'fraction_non_alphanumeric': 0.058465286236297195, 'fraction_numerical': 0.018270401948842874, 'mean_word_length': 5.134328358208955, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Protective effect of an alpha 2-adrenoceptor antagonist, midaglizole, against allergen-provoked late asthmatic responses.

We investigated the effects of midaglizole (MID) on the allergen-provoked early and late asthmatic response (EAR, LAR) in a randomized, single-blind protocol. Four subjects with allergic asthma inhaled the following combinations: (1) allergen alone (control phase); (2) (a) pre- and posttreatment with MID (oral administration of 200 mg), (b) pretreatment with MID (200 mg), or (c) posttreatment with MID (200 mg). MID significantly inhibited the LAR in the three treatment phases (p < 0.05). However, the EAR was not inhibited significantly. These results suggest that MID may participate in the inhibition of the allergen-provoked LAR and may play an important clinical role as an anti-LAR agent.